Pregled bibliografske jedinice broj: 1244139
European Registry on Helicobacter pylori management (Hp--EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients
European Registry on Helicobacter pylori management (Hp--EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients // Gut, 70 (2021), 1; 40-54 doi:10.1136/gutjnl-2020-321372 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1244139 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
European Registry on Helicobacter pylori
management (Hp--EuReg): patterns and trends in
first-line empirical eradication prescription and
outcomes of 5 years and 21 533 patients
Autori
Nyssen, OP ; Bordin, D ; Tepes, B ; Perez-Aisa, A ; Vaira, D ; Caldas, M ; Bujanda, L ; Castro-Fernandez, M ; Lerang, F ; Leja, M ; Rodrigo, L ; Rokkas, T ; Kupcinskas, L ; Perez-Lasala, J ; Jonaitis, L ; Shvets, O ; Gasbarrini, A ; Simsek, H ; Axon, ATR ; Buzas, G ; Machado, JC ; Niv, Y ; Boyanova, L ; Goldis, A ; Lamy, V ; Tonkić, A ; Przytulski, K ; Beglinger, C ; Venerito, M ; Bytzer, P ; Capelle, L ; Milosavljevic, T ; Milivojevic, V ; Veijola, L ; Molina-Infante, J ; Vologzhanina, L ; Fadeenko, G ; Arino, I ; Fiorini, G ; Garre, A ; Garrido, J ; Perez, CF ; Puig, I ; Heluwaert, F ; Megraud, F ; O'Morain, C ; Gisbert, JP
Kolaboracija
Hp-EuReg Investigators
Izvornik
Gut (0017-5749) 70
(2021), 1;
40-54
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
TRIPLE THERAPY ; QUADRUPLE THERAPY ; CONSENSUS ; INFECTION ; METAANALYSIS ; CLARITHROMYCIN ; GUIDELINES ; RESISTANCE ; ARTICLE
Sažetak
Objective The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. Design International multicentre prospective non- interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG- REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed. Results 30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14- day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). Conclusion Management of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE